Argenx, Zai Lab Shares Rise After Positive Trial Results for Vyvgart Hytrulo
By Chris Wack
Argenx shares were up 25% to $474.87 in premarket trading after the company said it and Zai Lab saw positive topline results from their study evaluating Vyvgart Hytrulo, or efgartigimod alfa and hyaluronidase-qvfc, in adults with chronic inflammatory demyelinating polyneuropathy.
Zai Lab shares were up 10% to $30.49 in premarket trading.
The companies said the study met its primary endpoint, demonstrating a significantly lower risk of relapse with Vyvgart Hytrulo compared with placebo.
The study showed that the safety and tolerability profile was consistent with confirmed safety profile of Vyvgart, and 91% of eligible patients continued to the next phase of the open-label extension study.
The most frequent treatment-related adverse event was injection site reactions, which occurred in a lower percentage of patients than previous Vyvgart Hytrulo trials. All injection site reactions were mild to moderate and resolved over time.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
July 17, 2023 06:55 ET (10:55 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
Alibaba Earnings: More Positive Outlook Despite Mixed Results
-
After Earnings and a 56% Rally In 2024, Is Arm Stock a Buy, a Sell, or Fairly Valued?
-
How Morningstar Rates Stocks
-
After Earnings, Is Disney Stock a Buy, a Sell, or Fairly Valued?
-
Home Depot Earnings: Macro Factors Pinch Demand, but Long-Term Outlook Intact
-
Tariffs On Chinese EVs Offer US Automakers a Chance to Capture Demand
-
The Best REITs to Buy
-
3 Hot Stocks to Buy That Still Look Undervalued